152 related articles for article (PubMed ID: 37818554)
1. New Molecular Markers for Prostate Cancer Diagnosis.
Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
3. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
4. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
5. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
[TBL] [Abstract][Full Text] [Related]
6. An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs.
Bilal M; Javaid A; Amjad F; Youssif TA; Afzal S
Transl Oncol; 2022 Dec; 26():101542. PubMed ID: 36148731
[TBL] [Abstract][Full Text] [Related]
7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
8. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis.
Matuszczak M; Schalken JA; Salagierski M
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282798
[TBL] [Abstract][Full Text] [Related]
10. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
[TBL] [Abstract][Full Text] [Related]
11. Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J; Borque-Fernando A; Esteban LM; Mascarós JM; Ramírez-Backhaus M; Casanova J; Collado A; Mir C; Gómez-Ferrer A; Wong A; Aragón F; Calatrava A; López-Guerrero JA; Groskopf J; Schalken J; Van Criekinge W; Domínguez-Escrig J
Prostate; 2020 May; 80(6):500-507. PubMed ID: 32077525
[TBL] [Abstract][Full Text] [Related]
12. Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Nowroozi M; Ayati M; Jamshidian H; Arbab A; Ghorbani H; Amini E; Hakima H; Salehi S; Ghadian A
Nephrourol Mon; 2015 Mar; 7(2):e26752. PubMed ID: 25821749
[TBL] [Abstract][Full Text] [Related]
13. Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.
Lima AR; Bastos Mde L; Carvalho M; Guedes de Pinho P
Transl Oncol; 2016 Aug; 9(4):357-70. PubMed ID: 27567960
[TBL] [Abstract][Full Text] [Related]
14. Digital rectal examination is barrier to population-based prostate cancer screening.
Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
[TBL] [Abstract][Full Text] [Related]
16. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Urinary prostate-specific antigen and microseminoprotein-beta levels in men with and without prostate cancer: A prospective cohort study.
Shrivastava P; Garg H; Bhat M; Dinda A; Kumar R
Indian J Urol; 2020; 36(1):50-55. PubMed ID: 31983827
[TBL] [Abstract][Full Text] [Related]
20. Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination.
Frantzi M; Culig Z; Heidegger I; Mokou M; Latosinska A; Roesch MC; Merseburger AS; Makridakis M; Vlahou A; Blanca-Pedregosa A; Carrasco-Valiente J; Mischak H; Gomez-Gomez E
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
